Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1251-1260

  Johnsen, Hans Erik ^a   Bergkvist, Kim Steve ^a   Schmitz, Alexander ^a   Kjeldsen, Malene Krag ^a   Hansen, Steen Moller ^a   Gaihede, Michael ^a   Norgaard, Martin Agge ^a   Bæch, John ^a   Gronholdt, Marie Louise ^a   Jensen, Frank Svendsen ^a   Johansen, Preben ^a   Bodker, Julie Stove ^a   Bogsted, Martin ^a   Dybkær, Karen ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Cell of origin; Cell sorting; Flow cytometry; Gene expression profiling

Indexed keywords

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; DNA MODIFICATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GERMINAL CENTER; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; MEMORY CELL; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; GENETICS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; PROCEDURES; STATISTICAL MODEL;

TRANSCRIPTOME;

B-LYMPHOCYTES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS; MODELS, STATISTICAL; MULTIPLE MYELOMA; TRANSCRIPTOME;

EID: 84901354501     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.839785     Document Type: Review

References (88)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classifi cation of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011; 117: 5019-5032
2. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-3967
3. Mateo G, Montalbán MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/ GEM cooperative study groups on patients uniformly treated wiThhigh-Dose therapy. J Clin Oncol 2008; 26: 2737-2744
4. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100: 3095-3100. (Pubitemid 35217054
5. Nolan GP. Flow cytometry in the post fl uorescence era. Best Pract Res Clin Haematol 2011; 24: 505-508
6. Paiva B, Almeida J, Pé rez-Andrés M, et al. Utility of fl ow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 2010; 78: 239-252
7. Van Dongen J J, Lhermitte L, Bö t tcher S, et al. EuroFlow antibody panels for standardized n-Dimensional fl ow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975
8. Rawstron A C, Orfao A, Beksac M, et al. European Myeloma Network. Report of the European Myeloma Network on multiparametric fl ow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438
9. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-322
10. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313
11. Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187. (Pubitemid 37328787
12. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell defi nitions and terminology: The devil is in the details. Nat Rev Cancer 2012; 12: 767-775
13. Rasmussen T, Kuehl M, Lodahl M, et al. Possible roles for activating RAS mutations in MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317-323. (Pubitemid 40053099
14. Killmann S A. A cute leukaemia: Development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the sleeper-To-feeder stem cell hypothesis. Baillieres Clin Haematol 1991; 4: 577-598
15. Johnsen HE, Kjeldsen MK, Urup T, et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer 2009; 45(Suppl. 1): 194-201
16. Boman BM, Wicha MS. Cancer stem cells: A step toward the cure. J Clin Oncol 2008; 26: 2795-2799
17. Martinez-Climent J A, Fontan L, Gascoyne R D, et al. Lymphoma stem cells: Enough evidence to support their existence? Haematologica 2010; 95: 293-302
18. Schmitz R, RennéC, Rosenquist R, et al. Insights into the multistep transformation process of lymphomas: IgH-Associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin' s and non-Hodgkin' s lymphomas. Leukemia 2005; 19: 1452-1458. (Pubitemid 41136341
19. Matthias P, Rolink AG. Transcriptional networks in developing and mature B-cells. Nat Rev Immunol 2005; 5: 497-508. (Pubitemid 40835037
20. Klein U, Dalla-Favera R. Germinal centres: Role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8: 22-33
21. McHeyzer-Williams M, Okitsu S, Wang N, et al. Molecular programming of B-cell memory. Nat Rev Immunol 2011; 12: 24-34
22. Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity 2007; 27: 190-202. (Pubitemid 47284923
23. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), apotential RNA editing enzyme. Cell 2000; 102: 553-563
24. Perez-Andres M, Paiva B, Nieto WG, et al. Human peripheral blood B-cell compartments: A crossroad in B-cell traffi c. Cytometry B Clin Cytom 2010; 78(Suppl. 1): S47-S60
25. Kjeldsen MK, Perez-Andres M, Schmitz A, et al. Multiparametric fl ow cytometry for identifi cation and fl uorescence activated cell sorting of fi ve distinct B-cell subpopulations in normal tonsil tissue. Am J Clin Pathol 2011; 136: 960-969
26. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. JExp Med 2008; 205: 2251-2268
27. Eckerle S, Brune V, Dö ring C, et al. Gene expression profi ling of isolated tumour cells from anaplastic large cell lymphomas: Insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23: 2129-2138
28. Tiacci E, Dö ring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120: 4609-4620
29. Bergkvist KS, Nyegaard M, Bø gsted M, et al. Amodifi ed method for microarray gene expression profi ling of minor B-cell subpopulations in man. Submitted 2013
30. Pajares MJ, Ezponda T, Catena R, et al. Alternative splicing: An emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-357. (Pubitemid 46464532
31. Shmueli G. To explain or to predict? S tat Sci 2 010; 2 5: 2 89-3 10
32. Speed T. Statistical analysis of gene expression microarray data. Boca Raton, FL: Chapman & Hall/CRC; 2003
33. Knudsen S. Abiologist's guide to analysis of DNA microarray data. New York: John Wiley & Sons; 2002
34. Gentleman R, Carey V, Huber W, et al ., editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005
35. Smyth GK. Linear models and empirical bayes methods for assessing diff erential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3
36. Benjamini Y, Hochberg Y, Controlling the false discovery rate: A practical and powerful approach to multiple testing. JR Stat Soc B 1995; 57: 289-300
37. Tibshirani R, Hastie T, Narasimhan B, et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567-6572. (Pubitemid 34526173
38. Fan J, Fan Y. High dimensional classifi cation using features annealed independence rules. Ann Stat 2008; 36: 2605-2637
39. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. JStat Softw 2010; 33: 1-22
40. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80
41. The R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010
42. Bergsagel P L, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931-13936. (Pubitemid 26424223
43. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429
44. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling. Nature 2000; 403: 503-511. (Pubitemid 30082188
45. Hummel M, Bentink S, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic defi nition of Burkitt's lymphoma from transcriptional and genomic profi ling. N Engl J Med 2006; 354: 2419-2430
46. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diff use large B-cell lymphoma. Nat Genet 2011 ; 43: 830-837
47. Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B-cell-like diff use large B-cell lymphoma. JExp Med 2007; 204 : 633-643. (Pubitemid 46457085
48. Shaff er AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell diff erentiation. Immunity 2004; 21: 81-93
49. Seifert M, Kuppers R. Molecular footprints of a germinal center derivation of human IgM-(IgD-) CD27-B-cells and the dynamics of memory B-cell generation. JExp Med 2009; 206 : 2659-2669
50. Pasqualucci L, Guglielmino R, HouldsworthJ, et al. Expression of the AID protein in normal and neoplastic B-cells. Blood 2004 ; 104: 3318-3325. (Pubitemid 39507152
51. Lenz G, Wright G W, Emre N C, et al. Molecular subtypes of diff use large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525
52. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B-cell-like but not in activated B-cell-like diff use large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209-10213
53. Kü p pers R, Klein U, Hansmann M L, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520-1529
54. Bergkvist K, Bø gsted M, Schmitz A, et al. Characterization of memory B-cells from thymus and its impact for DLBCL classifi cation. In preparation 2013
55. Kyle AR, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873
56. Hallek M, Bergsagel P L, Anderson K C. M ultiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21. (Pubitemid 28018724
57. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303. (Pubitemid 40967205
58. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profi ling of multiple myeloma, monoclonal gammopathy of undetermined signifi cance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757. (Pubitemid 34533050
59. Bergsagel PL, Kuehl M. Chromosome translocation in multiple myeloma. Oncogene 2001; 20: 5611-5622
60. Bergsagel P L, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931-13936. (Pubitemid 26424223
61. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated wiThincreased expression and activating mutations of fi broblast growThfactor receptor 3. Nat Genet 1997; 16: 260-264. (Pubitemid 27280209
62. Rasmussen T, Theilgaard-Mönch K, Hudlebusch HR, et al. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: Indications for diff erent disease entities. Br J Haematol 2003; 123 : 253-262. (Pubitemid 37305059
63. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003; 102: 4504-4511. (Pubitemid 37494117
64. Fenton J A, Pratt G, Rawstron A C, et al. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene 2003; 22: 1103-1113. (Pubitemid 36313154
65. Chapman M A, Lawrence M S, Keats J J, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011 ; 471: 467-472
66. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066
67. Leich E, Wei ß bach S, Klein HU, et al. Multiple myeloma is aff ected by multiple and heterogeneous somatic mutations in adhesionand receptor tyrosine kinase signaling molecules. Blood Cancer J 2013; 3: E102
68. Vicente-Due ñ as C, Romero-Camarero I, González-Herrero I, et al. Anovel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 2012; 31: 3704-3717
69. Rasmussen T, Lodahl M, Hancke S, et al. In multiple myeloma clonotypic CD38-/CD19-/ CD27-memory B-cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004; 45: 1413-1417
70. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197. (Pubitemid 351380120
71. Paí no T, Ocio EM, Paiva B, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated wiTha cancer stem cell phenotype. Haematologica 2012; 97: 1110-1114
72. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94 : 3576-3582. (Pubitemid 29536154
73. Guikema JE, Vellenga E, Bakkus MH, et al. Myeloma clonotypic B-cells are hampered in their ability to undergo B-cell diff erentiation in vitro. Br J Haematol 2002; 119: 54-61. (Pubitemid 35176498
74. Rasmussen T, Jensen L, Johnsen HE. The clonal hierarchy in multiple myeloma. Acta Oncol 2000; 39: 765-770
75. Pfeifer S, Perez-Andres M, Ludwig H, et al. Evaluating the clonal hierarchy in light-chain multiple myeloma: Implications against the myeloma stem cell hypothesis. Leukemia 2011; 25 : 1213-1216
76. Van Valckenborgh E, Matsui W, Agarwal P, et al. Tumor-initiating capacity of CD138-And CD138-Tumor cells in the 5T33 multiple myeloma model. Leukemia 2012; 26: 1436-1439
77. Christensen JH, Jensen PV, Kristensen IB, et al. Characterization of potential CD138 negative myeloma stem cells. Haematologica 2012; 97: E18-e20
78. Rasmussen T, Honore L, Johnsen HE. Identifi cation and characterization of malignant cells using RT-PCR on single fl ow sorted cells. Med Oncol 1998; 15: 96-102. (Pubitemid 28442575
79. Rasmussen T, Haaber J, Dahl IM, et al. Identifi cation of translocation products but not K-RAS mutations in memory B cells from patients wiThmultiple myeloma. Haematologica 2010 ; 95: 1730-1737
80. Rasmussen T, Jensen L, Johnsen HE. The CD19 compartment in myeloma includes a population of clonal cells persistent after high-Dose treatment. Leuk Lymphoma 2002; 43: 1075-1077. (Pubitemid 34460893
81. Rasmussen T, Jensen L, HonoréL, et al. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000; 96 : 4357-4359
82. Rasmussen T, Johnsen H E. Controversies surrounding the circulating clonotypic B lymphocytes in multiple myeloma. Response to: Clonotypic B cells in the peripheral blood of patients wiThmultiple myeloma. Blood 2001; 97: 2913-2914
83. Rasmussen T, Jensen L, Johnsen HE. Levels of circulating CD19-cells in patients wiThmultiple myeloma. Blood 2000 ; 95: 4020-4021. (Pubitemid 30412889
84. Rasmussen T, Jensen L, HonoréL, et al. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-Time RT-PCR assays. Br J Haematol 1999; 107 : 818-824. (Pubitemid 30020156
85. Rasmussen T, Kastrup J, Knudsen L M, et al. High numbers of clonal CD19-cells in the peripheral blood of a patient wiThmultiple myeloma. Br J Haematol 1999; 105: 265-267. (Pubitemid 29197169
86. Irish J M, Myklebust J H, Alizadeh A A, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 2010; 107: 12747-12754
87. Irish JM, Czerwinski DK, Nolan GP, et al. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecifi c fl ow cytometry. JImmunol 2006; 177: 1581-1589. (Pubitemid 44092493
88. Irish JM, Czerwinski DK, Nolan GP, et al. Altered B-cell receptor signaling kinetics distinguishes human follicular lymphoma B cells from tumor-infi ltrating nonmalignant B cells. Blood 2006 ; 108: 3135-3142